Sanne de Bruin

115 InPUT- pilot study in the Netherlands to a platelet transfusion was at 216x10 9 /L, received by a patient who used double an- ti-platelet therapy, and these concentrates were administrated in the operating theatre. Eight (72.7%) times one unit of platelets was transfused and three (27.3%) times two units were transfused. In all cases where more than one unit was transfused, patients were undergoing a procedure or were bleeding. In three (27.3%) cases, irradiated platelet concentrates were administered. One platelet concentrate (9%) was derived by apheresis and ten concentrates (91%) were pooled buffy coat products, obtained from five different donors. The majority (81.8%) of the platelet concentrates were ad- ministered in one single patient. Plasma transfusion and coagulation factors Prothrombin time (PT) remained stable during ICU stay. The median highest PT was 12.0 (10.9-12.5) sec at day one and 11.5 (10.8-13.6) sec at day seven of ICU stay. 1.7% of the reported PT values were greater than 20 sec (figure 2C). A third of the patients had a normal aPTT during their whole ICU stay (aPTT <33 sec). The median aPTTwas 26 (24-32) sec at day one and 23 (21-26.5) sec at day seven of ICU stay (Figure 2D). In nine (19%) of the patients an aPTT >40 sec was observed at some moment during their stay at the ICU. Two patients received plasma transfusion during the study period. Themean PTwas 12.6 sec pre- and 12.6 sec post-transfusion. In both cases, no ROTEM was performed prior transfusion. In three (6.3%) different patients, five times tranexamic acid administration was reported. In 80% of these cases, the main reason of administering was bleeding. Three fibrinogen transfusions were recorded in one single patient, twice prior to an invasive procedure and once when actively bleeding. In one event, ROTEM was per- formed prior fibrinogen transfusion. In all three events, the fibrinogen target was >2.0 g/L. Prothrombin complex was transfused once during the study period. Patient outcome Patient outcome was measured at day 28 (table 3). Median observed ICU length of stay was two days (2-4.25). Six patients (12.2%) were admitted to the ICU for more than seven days. Two patients were still in ICU at 28 days. Mortality in the study cohort was thirteen percent. In patients without any RBC, platelet or plasma transfusion the mortality was 10% versus 25% in the group who did receive one or more RBC, platelet or plasma transfusions (p=0.24). 4